About this trial
Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.
The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age ≥19
Able to provide written, informed consent
Able to attend an in-person study visit in Omaha, NE twice a year to collect blood samples
Must also meet criteria for one specific cohort. Participants who meet criteria for more than one cohort are eligible. (The intent being that potential participants must meet the criteria for at least one cohort, but are eligible if criteria are met for more than one cohort)
Disqualifiers
Personal history of pancreatic ductal adenocarcinoma (PDAC)
Currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)
Pre-diabetes on metformin for ≥ 3 years
Trial population
In order to obtain a resource of clinical data and longitudinally obtained, annotated blood specimens and to develop an enriched population to prospectively evaluate a sensitive and specific biomarker, subjects from the following 3 groups at higher than average risk of pancreatic ductal adenocarcinoma (PDAC) will be recruited and enrolled. New onset diabetes, high risk pre-diabetes Pancreatic cystic neoplasms and pancreatitis Familial risk
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Number of pancreas cancer cases diagnosed.
Number of pancreas cancer cases diagnosed.
Biomarkers which may predict early pancreas cancer.
Biomarkers which may predict early pancreas cancer.
Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.
Result of MMTT which may indicate type 3c diabetes, which may be a risk factor
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Nebraska
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Virginia Mason Hospital/Medical Center
Collaborator
VA Nebraska Western Iowa Health Care System
Collaborator